MedTrace Logo

Prospective Metabolic Monitoring of Youth and Adults With Bipolar Disorder

NCT01282281 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2014-01-17

No results posted yet for this study

Summary

Background: Most psychotropic medications that are effective in the treatment of Bipolar Disorder (BD) are associated with endocrine-metabolic changes (EMCs). To date, there is no long-term study in BD that has examined specifically the association of inflammation with EMCs in BD. Specific aims: 1) to identify predictors of EMCs among adolescents and adults with BD who are being started on a medication ; 2) to compare change in EMCs in youth and adults treated for BD; 3) to measure change in EMCs associated with use of different medications for BD. Research Design: Participants: 30 adolescents (14-18 years old) with BD and 30 adults (19-65 years old) with BD. Measures: Blood levels of biomarkers that are associated with EMCs will be measured.

Conditions

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Dr. Ayal Schaffer

    lead OTHER

Principal Investigators

  • Ayal Schaffer, MD · Sunnybrook Health Sciences Centre

  • Benjamin Goldstein, MD · Sunnybrook Health Sciences Centre

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-01-31
Completion
2013-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282281 on ClinicalTrials.gov